Session » Posters: Clinical and Therapeutic I

Date: Thursday, March 30, 2023

Time: 6:00PM-7:00PM

Meeting: 2023 Pediatric Rheumatology Symposium

6:00PM-7:00PM: Abstract Number: 057

A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE)

6:00PM-7:00PM: Abstract Number: 056

An Advanced Physiotherapist Practitioner Model of Care Is Ideally Suited to Address Workforce Concerns in Pediatric Rheumatology: A Retrospective Chart Review

6:00PM-7:00PM: Abstract Number: 060

Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?

6:00PM-7:00PM: Abstract Number: 062

Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

6:00PM-7:00PM: Abstract Number: 053

Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study

6:00PM-7:00PM: Abstract Number: 067

Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis

6:00PM-7:00PM: Abstract Number: 047

Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide

6:00PM-7:00PM: Abstract Number: 077

Clinical Characteristics of Chronic Recurrent Multifocal Osteomyelitis or Chronic Nonbacterial Osteomyelitis in Pediatrics; Single Center Study in Korea

6:00PM-7:00PM: Abstract Number: 074

Clinical Characteristics of Juvenile Systemic Sclerosis in Korea: A 30-year Single Center Study

6:00PM-7:00PM: Abstract Number: 071

Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort

6:00PM-7:00PM: Abstract Number: 041

Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort

6:00PM-7:00PM: Abstract Number: 046

Colchicine Adherence Among Children and Young Adults with Familial Mediterranean Fever During Treatment with interleukin-1 Inhibitors

6:00PM-7:00PM: Abstract Number: 048

Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study

6:00PM-7:00PM: Abstract Number: 055

COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey

6:00PM-7:00PM: Abstract Number: 076

COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic

6:00PM-7:00PM: Abstract Number: 054

Craniofacial Localized Scleroderma: A Single Center Retrospective Cohort

6:00PM-7:00PM: Abstract Number: 043

Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)

6:00PM-7:00PM: Abstract Number: 075

Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome

6:00PM-7:00PM: Abstract Number: 052

Extreme Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA): A Discrete Group of Patients

6:00PM-7:00PM: Abstract Number: 073

Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy

6:00PM-7:00PM: Abstract Number: 058

High Levels of Psychological Distress, Depression, and Anxiety Symptoms in Children with Pediatric Rheumatologic Diseases

6:00PM-7:00PM: Abstract Number: 063

JAK Inhibition in down Syndrome Associated Arthritis (DA) – Our Experience to Date with Tofacitinib in 5 Patients

6:00PM-7:00PM: Abstract Number: 051

Juvenile Relapsing Polychondritis: A Single Center Cohort

6:00PM-7:00PM: Abstract Number: 072

Musculoskeletal Ultrasound Findings in Children with Psoriasis

6:00PM-7:00PM: Abstract Number: 069

Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios of Patients with Juvenile Systemic Lupus Erythematosus

6:00PM-7:00PM: Abstract Number: 068

Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

6:00PM-7:00PM: Abstract Number: 045

Patient Reported Outcomes in Pediatric Vasculitis

6:00PM-7:00PM: Abstract Number: 050

Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort

6:00PM-7:00PM: Abstract Number: 042

Prevalence of Chronic Pain in Childhood-onset Systemic Lupus Erythematosus and Juvenile Dermatomyositis

6:00PM-7:00PM: Abstract Number: 065

Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA

6:00PM-7:00PM: Abstract Number: 066

Telemedicine Use in the Assessment of Juvenile Myositis: A Mixed-Methods Study of an International Healthcare Provider Experience

6:00PM-7:00PM: Abstract Number: 070

The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies

6:00PM-7:00PM: Abstract Number: 064

Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis

6:00PM-7:00PM: Abstract Number: 059

Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort

6:00PM-7:00PM: Abstract Number: 044

Validation of Newly Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis: A Virginia Cohort

6:00PM-7:00PM: Abstract Number: 061

Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey

6:00PM-7:00PM: Abstract Number: 049

What Happens After Juvenile Myositis Patients Screen Positive for Mental Health Comorbidities? Update from a Multicenter Juvenile Myositis Mental Health Screening Pilot Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].